Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMIT-CD: mirikizumab plus tirzepatide in adults with active Crohn's disease and obesity or overweight
NL-OMON61045Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirikizumab and tirzepatide in Crohn's disease, obesity and Overweight, sponsored by Eli Lilly and Company. Started Nov 2025; status: recruiting.
02
Drugs
mirikizumabtirzepatide
03
Conditions
Crohn's diseaseobesityOverweight
Beyond the preview
Go deeper on NL-OMON61045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61045.